PRISM MarketView

OS Therapies (OSTX) Releases Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Utilizing Tunable Antibody Drug Conjugate (tADC) Platform

New York, September 11, 2024 - PRISM MarketView - The clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, OS Therapies (OSTX) today announced positive data in animal models of ovarian cancer for its first therapeutic candidate developed ba...

11 September 2024

Terns Pharmaceuticals Announces Public Offering Following Positive Data on Weight-Loss Drug

New York, September 11, 2024 - PRISM MarketView - Terns Pharmaceuticals (Nasdaq: TERN) has announced an upsized public offering of 11.9 million shares of common stock at $10.50 per share, with expected gross proceeds of approximately $150.15 million. This announcement fo...

11 September 2024

New Tilray Medical Study on Medical Cannabis Highlights Reduced Pain and Improved Sleep for Fibromyalgia Patients

New York, September 10, 2024 - PRISM MarketView - Tilray Medical, a division of Tilray Brands, Inc. (Nasdaq: TLRY) and a leading global player in the medical cannabis sector, recently released a new study, “Treatment in Pain Management and Other Fibromyalgia-Associated S...

10 September 2024

Aclarion Technology Advances Global Validation with First Nociscan Exams in LIFEHAB Trial on Low Back Pain

New York, September 10, 2024 - PRISM MarketView - Aclarion, Inc. (Nasdaq: ACON), a healthcare technology company focused on leveraging biomarkers and augmented intelligence to identify chronic low back pain, announced the completion of the first exams in its ongoing LIFE...

10 September 2024

Aclarion Added to PRISM Emerging Medical Devices Index

· Company's industry-first technology addresses chronic low back pain

6 September 2024

Lisata Therapeutics Secures FDA Orphan Drug Designation for Certepetide in Treating Aggressive Bile Duct Cancer

New York, September 06, 2024 - PRISM MarketView - Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing therapies for advanced solid tumors, has announced that its investigational drug, certepetide, has been granted Orphan Drug Desi...

6 September 2024

Aclarion Inc. (ACON) Launches Statewide Initiative to Deliver Advanced Personal Injury and Workers Compensation Diagnostics with AI Technology

New York, September 05, 2024 - PRISM MarketView - Aclarion, Inc. (Nasdaq: ACON), a healthcare technology company utilizing biomarkers and AI algorithms to improve the diagnosis of chronic low back pain, announced a new partnership aimed at applying its Nociscan technolog...

5 September 2024

Veru Inc. (VERU) Advances Muscle Preservation Research with Enobosarm and Strengthens Financial Position

New York, September 03, 2024 - PRISM MarketView - PRISM Emerging Weight Loss Index mover Veru Inc. (NASDAQ: VERU), is actively advancing its research and development efforts, particularly in its Phase 2b QUALITY clinical study for enobosarm—a drug designed to preserve mu...

4 September 2024

PRISM MarketView Launches Emerging Weight Loss Index

New York, September 03, 2024 - PRISM MarketView - According to the World Health Organization (WHO), worldwide adult obesity has more than doubled since 1990, and adolescent obesity has quadrupled. In 2022, 1 in 8 people in the world or 890 million people were living with...

3 September 2024

PRISM Weight Loss Index Leader LEXX Soars 24% on Positive DehydraTECH-Processed Rybelsus® Study Results

New York, August 30, 2024 - PRISM MarketView - Lexaria Bioscience Corp. (NASDAQ: LEXX), today’s standout in the PRISM Weight Loss Index, saw its shares surge 24% following the announcement of promising results from its second human pilot study, GLP-1-H24-2. The study hig...

30 August 2024